Metyrapone - HRA Pharma
Alternative Names: Cormeto; Metirapona; Metopiron; Metopirone; Metycor; SU 4885Latest Information Update: 29 Nov 2022
At a glance
- Originator Novartis
- Developer HRA Pharma; Novartis
- Class Antidepressants; Antihormones; Diagnostic agents; Pyridines
- Mechanism of Action Steroid 11-beta-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Adrenal insufficiency; Cushing syndrome; Hyperaldosteronism
Most Recent Events
- 29 Nov 2022 No development reported - Phase-III for Cushing syndrome in Turkey, Romania (PO)
- 02 May 2022 HRA Pharma has been acquired by Perrigo
- 06 Oct 2020 Phase-III clinical trials in Cushing syndrome in Romania (PO) (NCT02297945)